MEDICILON

contact us krjpencn

뉴스현황

Press Events

현재 위치: > 뉴스현황 > Press Events > DNA-Vitamin E Comple...

DNA-Vitamin E Complex Works as Potent Gene Silencer

저자:   업로드:2015-08-18  조회수:

    Gene silencing is an effective method for turning down or off the aberrant genetic message that leads toward disease phenotypes. Therapeutics that takes advantage of this technology are beginning to enter the market. However, opportunities still remain for improving the efficient delivery of nucleic acid drugs to the relevant diseased tissues.

 

    Now, a team of researchers from the Tokyo Medical and Dental University and Osaka University have developed a new oligonucleotide complex, called heteroduplex oligonucleotide (HDO), that they have observed to be significantly potent at reducing the levels of target RNA while simultaneously lowering side effects, such as liver dysfunction.

 

    "Two major types of RNA targeting oligonucleotide drugs are currently being developed as therapeutic platforms for reduction of target gene expression—short interfering RNA (siRNA) and RNase H dependent antisense oligonucleotides (ASO)," explained senior author Takanori Yokota, M.D., Ph.D., professor in the department of neurology and neurological science at Tokyo Medical and Dental University.


    Insufficient delivery, poor cellular uptake of oligonucleotides, and their inefficient access to target RNA are major impediments to in vivo silencing methods.  Dr. Yokota and his team saw an opportunity to design a better oligo, developing the short DNA/RNA HDO molecule. HDO is composed of DNA/locked nucleic acid gapmer as ASO and its complementary RNA strand.


    "HDO has a structure different from double-stranded RNA used for siRNA and single-stranded DNA used for ASO, and different functional molecular mechanisms from siRNA or ASO in the cells," said Dr. Yokota.


    "When α-tocopherol (vitamin E) as drug delivery moiety is conjugated to ASO directly, its silencing effect is reduced because the conjugated lipid interferes with the mechanisms of ASO,” Dr. Yokota continued. “On the other hand, when α-tocopherol is conjugated to cRNA of HDO, an α-tocopherol molecule can improve the delivery of HDO to the liver by five times, making the gapmer DNA strand active by releasing it from HDO through the cleavage of cRNA by cellular nucleases."


    The investigators found that the Toc-HDO was markedly more potent at reducing the target mRNA, in this instance to lower serum LDL levels, when compared to the parental ASO strand. Specifically, the Toc-HDO was 22 times more potent at reducing Apolipoprotein B mRNA than the parent ASO within the liver. Moreover, the pharmacological effects lasted for more than a month with a single injection.


    The findings from this study were published recently in Nature Communications through an article entitled “DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing.”

이전:Novel Enzyme Finding Points Way to Improved Cognitive Therapies

다음에:Engineering Therapeutic Proteins into Antibodies